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Abstract: Purpose: Left ventricular (LV) mechanics are impaired in patients with severe aortic stenosis
(AS). Transcatheter aortic valve replacement (TAVR) has become a widespread technique for patients
with severe AS considered inoperable or high risk for open surgery. This procedure could have a positive
impact in LV mechanics. The aim of the study was to evaluate the effect of TAVR on LV function
recovery, as assessed by myocardial deformation parameters, both immediately and in the long term.
Methods: One-hundred nineteen consecutive patients (81.2 ± 6.9 years, 50.4% female) from 10 centres
in Europe with severe AS who successfully underwent TAVR with either a self-expanding CoreValve
(Medtronic, Minneapolis, MN, USA) or a mechanically expanded Lotus valve (Boston Scientific, Natick,
MA, USA) were enrolled in a prospective observational study. A complete echocardiographic examination
was performed prior to device implantation, before discharge and 1 year after the procedure, including
the assessment of LV strain using standard 2D images. Results: Between baseline and discharge, only
a modest but statistically significant improvement in GLS (global longitudinal strain) could be seen
(GLS% –14.6 ± 5.0 at baseline; –15.7 ± 5.1 at discharge, p = 0.0116), although restricted to patients in
the CoreValve group; 1 year after the procedure, a greater improvement in GLS was observed (GLS% –17.1
± 4.9, p < 0.001), both in the CoreValve and the Lotus groups. Conclusions: Immediate and sustained
improvement in GLS was appreciated after the TAVR procedure. Whether this finding continues to be
noted in a more prolonged follow-up and its clinical implications need to be assessed in further studies.
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Abstract
Purpose: Left ventricular (LV) mechanics are impaired in pa-
tients with severe aortic stenosis (AS). Transcatheter aortic 
valve replacement (TAVR) has become a widespread tech-
nique for patients with severe AS considered inoperable or 
high risk for open surgery. This procedure could have a pos-
itive impact in LV mechanics. The aim of the study was to 
evaluate the effect of TAVR on LV function recovery, as as-
sessed by myocardial deformation parameters, both imme-
diately and in the long term. Methods: One-hundred nine-
teen consecutive patients (81.2 ± 6.9 years, 50.4% female) 
from 10 centres in Europe with severe AS who successfully 
underwent TAVR with either a self-expanding CoreValve 
(Medtronic, Minneapolis, MN, USA) or a mechanically ex-
panded Lotus valve (Boston Scientific, Natick, MA, USA) were 
enrolled in a prospective observational study. A complete 
echocardiographic examination was performed prior to de-
vice implantation, before discharge and 1 year after the pro-
cedure, including the assessment of LV strain using standard 
2D images. Results: Between baseline and discharge, only a 











































































(global longitudinal strain) could be seen (GLS% –14.6 ± 5.0 
at baseline; –15.7 ± 5.1 at discharge, p = 0.0116), although 
restricted to patients in the CoreValve group; 1 year after the 
procedure, a greater improvement in GLS was observed 
(GLS% –17.1 ± 4.9, p < 0.001), both in the CoreValve and the 
Lotus groups. Conclusions: Immediate and sustained im-
provement in GLS was appreciated after the TAVR proce-
dure. Whether this finding continues to be noted in a more 
prolonged follow-up and its clinical implications need to be 
assessed in further studies. © 2019 S. Karger AG, Basel
Introduction
Degenerative aortic stenosis (AS) is one of the most 
common cardiovascular diseases in developed countries, 
surpassed only by hypertension and coronary artery dis-
ease, and the most frequent valve disease requiring inter-
vention [1], given that valve replacement is the only ther-
apy that improves survival [2]. Moreover, the prevalence 
of this disease is increasing in ageing societies and so is 
the number of patients with associated comorbidities and 
high operative risk [1–3]. Over the past decade, trans-
catheter aortic valve replacement (TAVR) techniques 
have emerged as a novel therapeutic alternative for pa-
tients considered inoperable or high risk for surgery [4–
6]. Since the first-in-man experience in 2002 [7], thou-
sands of patients have been treated with this technique 
worldwide with a high procedural success rate [8].
Long-standing AS induces a series of adaptive re-
sponses to pressure overload that translate in changes in 
left ventricular (LV) geometry and performance, al-
though LV volume and ejection fraction (LVEF) may re-
main preserved in advanced stages of the disease [9]. The 
most important changes observed include hypertrophic 
remodelling with increased myocardial fibrosis [10], ab-
normal LV compliance and diastolic dysfunction [11, 12], 
elevated end-diastolic pressure [13] and impaired con-
tractility [14].
Echocardiography plays a central role in the success of 
a TAVR procedure, not only due to its importance in the 
pre-procedural evaluation, but also because it represents 
the best way for post-procedure follow-up.
Pre-procedurally, newer echocardiography methods 
like 2D speckle tracking analysis allow assessment of 
myocardial deformation as a sensitive marker for region-
al and global LV systolic function [15, 16]. It has been 
reported that despite normal ejection fraction, LV myo-
cardial deformation parameters such as global longitudi-
nal strain may be altered, and its detection can have prog-
nostic impact [17]. Strain imaging has demonstrated to 
be the most appropriate method to evaluate the subtle 
changes in systolic function that occur in patients with AS 
[18, 19] and global longitudinal strain (GLS) to be the 
most useful parameter to independently predict mortal-
ity [20]. Considering this, some ground-breaking work-
ing groups advocate for the use of GLS assessment as a 
tool for detecting high-risk asymptomatic patients that 
would benefit from an early valve intervention [21].
After valve replacement, TAVR has been associated 
with a faster and better recovery of LV function than sur-
gical aortic valve replacement in patients with AS and re-
duced ejection fraction [22]. Nevertheless, while improve-
ment in LV systolic function assessed by tissue Doppler 
and speckle tracking strain imaging has been observed af-
ter conventional surgical valve replacement in a mid- and 
long-term follow-up [14, 23–25], evidence about the ben-
efits of TAVR in LV mechanics is scarce. TAVR leads to 
an immediate reduction in LV afterload without the con-
founding effects of major surgery. Recent studies have an-
alysed LV function using strain imaging in patients after 
conventional TAVR implantation showing an improve-
ment in LVEF and longitudinal systolic deformation at 
1 year [26]. Others have also shown an acute regional im-
provement of myocardial systolic function measured by 
2D strain analysis immediately after TAVR, with no sig-
nificant changes in radial and circumferential functions or 
LVEF [27]. The acute haemodynamic effects of TAVR in 
LV diastolic performance, immediately after aortic valvu-
loplasty and prosthesis deployment have recently been as-
sessed showing an improvement in LV diastolic function 
parameters [28, 29].
The main objective of this study was to assess the im-
pact of TAVR on myocardial deformation parameters, 
both immediately after the procedure and in the long 
term. Additionally, we sought to evaluate the influence of 
the type of device on the evolution of myocardial defor-
mation parameters and to identify potential predictive 
factors of favourable evolution on myocardial strain.
Methods
Study Population and Protocol
This observational study was conducted prospectively at 10 
centres in Europe. Starting from October 2014 in the first partici-
pant centre until March 2015 in the last participant centre and 
during a period of 18 months, all consecutive patients with symp-
tomatic severe AS undergoing TAVR with either a self-expanding 
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mechanically expanded Lotus prosthesis (Boston Scientific, 
Natick, MA, USA) were eligible for inclusion. Exclusion criteria 
were poor echocardiographic window, defined as two or more in-
adequately visualized myocardial segments (17-segment model), 
atrial fibrillation, the existence of a concomitant unstable cardiac 
condition, such as an acute coronary syndrome or significant peri-
cardial effusion, or refusal to provide written informed consent.
An evaluation was planned at 3 points in time for all patients 
included in the study: a first visit (visit 1 or V1), prior to the proce-
dure, generally scheduled between 24 and 48 h before the implanta-
tion; a second visit (visit 2 or V2), scheduled on the planned day of 
discharge; and a last visit (final visit or FV) 1 year after the proce-
dure. Whenever possible, an intermediate visit (visit 3 or V3) was 
scheduled, approximately 6 months after the procedure. At each 
visit, patients underwent clinical and echocardiographic examina-
tion. All patients provided written informed consent. The study was 
approved by our ethics committee (CEIC code: 2013/049/20140731) 
and endorsed by the different committees at each participant centre.
Two-Dimensional Echocardiography
Echocardiographic examinations were performed using the 
available imaging equipment at each centre, provided that the same 
machine was used for all the examinations of any given patient. The 
ultrasound machines and softwares employed include: Vivid E9 
(GE Medical Systems, Horten, Norway) with EchoPac software, 
version 113.0.0; iE33, HD11, EPIQ7 (Philips Medical Systems, 
Bothell, WA, USA) with QLAB software, version 10.0; and Acuson 
S2000 (Siemens Medical Solution, Mountain View, USA) with Ve-
locity Vector Imaging, version 3.0. Digital loops were stored for 
off-line analysis, which was performed at each participant centre. 
The LV end-diastolic and end-systolic volumes were obtained at 
the standard apical 4-chamber and 2-chamber views, LVEF was 
calculated using Simpson’s rule. GLS was computed from the apical 
4-chamber, 2-chamber and 3-chamber views. Endocardial borders 
were traced by hand at an end-systolic and/or end-diastolic frame, 
according to the vendor, and myocardial speckles were automati-
cally tracked throughout subsequent frames. Whenever necessary, 
tracking was manually corrected. GLS was obtained as the average 
value of regional strains. Absolute reduction (abGLS) and percent-
age change in GLS (∆GLS) were calculated between V2, V3 or FV 
and V1. Other classic systolic and diastolic parameters were col-
lected according to current guidelines.
Statistical Analysis
All statistical analyses were performed using Stata 13.0. Con-
tinuous variables were expressed as mean ± standard deviation and 
compared with Student’s t test. Qualitative variables were ex-
pressed as percentage and compared with the χ2 test. To assess dif-
ferences in GLS, a paired t test was used to compare pre- and post-
procedural GLS at each point in time (this is, between V1 and V2, 
V3 or FV) and a 1-way repeated-measures ANOVA was run to 
determine whether there were differences in GLS along the differ-
ent time points considered. The predictive role of various anthro-
pometric and echocardiographic parameters was investigated by 
fitting a multivariable linear model with GLS(%) at FV as the out-
come. Possible explanatory outcomes were sex, gender, mean aor-
tic gradient, aortic valve area, GLS(%) at baseline, LVEF at V1, 
indexed mass of LV, LV end-diastolic volume, left atrial volume, 
mitral calcification and type of valve used.
Results
Patient Baseline Characteristics
The patient flow chart is presented in Figure 1. A total 
of 160 patients who underwent transcatheter aortic valve 
160 patients assessed for elegibility
41 patients excluded:
- Atrial fibrillation (n = 33)
- Poor echocardiographic window (n = 8)
119 patients enrolled in the study
V1
(n = 119)
14 patients lost to follow-up:
- Atrial fibrillation (n = 7)
- Logistics reasons (n = 6)
- Death (n = 1)
36 patients lost to follow-up:
- Not contacted (n = 18)
- Death (n = 9)
- Atrial fibrillation (n = 5)
- Refusal to come (n = 2)


















































































implantation at participant centres were assessed for eli-
gibility. 41 patients (25.6%) met the exclusion criteria, 33 
of them because of atrial fibrillation prior to device im-
plantation and 8 of them because of poor echocardio-
graphic window and thus were not enrolled in the study. 
Of the 119 patients included in the study, 43 treated with 
a CoreValve and 76 treated with a Lotus device, 7 devel-
oped atrial fibrillation after valve implantation (2 of them 
transient and 5 of them permanent), 6 lacked a complete 
pre-discharge echocardiographic examination because of 
logistic reasons and 1 died shortly after the intervention, 
leaving a population of 105 patients for analysis at V2 (41 
patients in the CoreValve group and 64 patients in the 
Lotus group). At the end of the study, 9 patients had died, 
2 had moved to another county, 2 refused to attend the 
visit, 5 had atrial fibrillation and 18 could not be contact-
ed, leaving a population of 69 patients for analysis at FV 
(37 patients in the CoreValve group and 32 patients in the 
Lotus group). Additionally, from the total population of 
119 patients, 53 patients without atrial fibrillation had a 
complete echocardiographic examination at 6 months, 
which was used for an intermediate analysis at V3.
Patient baseline characteristics are summarized in 
 Table 1. The median age was 81.2 ± 6.9 years and 50.4% 
were female. Concerning clinical data, 74.8% of patients 
had hypertension, 22.3% had diabetes mellitus and 14.6% 
had a history of coronary artery disease. More than half 
of the patients (53.5%) presented poor functional class 
(considered as such a NYHA classification of III or IV).
All 119 patients had severe AS: the aortic valve area 
was 0.75 ± 0.23 cm2, and the mean pressure gradient 
was 46.3 ± 15.0 mm Hg. A reduced LVEF (< 50%) was 
found in 30 of 119 patients (25.2%), with classical low-
flow  low-gradient state (LVEF < 50% and stroke volume 
index < 35 mL/m2) seen in 2 of 119 patients (1%) and 
paradoxical low-flow state (LVEF ≥50% and stroke vol-
ume index < 35 mL/m2) seen in 1 of 119 patients (0.8%). 
The indexed LV mass was 145.5 ± 45.9 g/m2, with 81 
Table 1. Baseline characteristics, including a comparison between patients receiving a CoreValve and a Lotus 
prosthesis
Global CoreValve Lotus p value
Anthropometric and clinical variables
Age, years 81.2±6.9 83.9±4.9 79.7±7.4 0.0013
Sex female, % 50.4 55.8 47.4 ns
Weight, kg 69±12.5 68.2±13.6 69.4±11.9 ns
Height, cm 161.6±9.2 159.1±8.0 163.1± 9.6 0.0253
BSA (Dubois) 1.73±0.18 1.70±0.19 1.75±0.18 ns
Hypertension, % 74.8 90.7 63.3 0.002
Diabetes, % 22.3 20.9 23.3 ns
CAD, % 14.6 9.3 18.3 ns
NYHA III–IV, % 53.5 69.8 37.2 0.002
Echocardiograpahic variables
Mean gradient, mm Hg 46.3±15.0 50.7±13.6 43.8±15.2 0.0159
Peak gradient, mm Hg 76.3±26.2 84.9±27.5 71.3±24.2 0.0065
AVA, m2 0.75±0.23 0.67±0.16 0.79±0.25 0.0058
Indexed AVA, cm2/m2 0.44±0.17 0.43±0.21 0.46±0.15 ns
LVEDV, mL 97.8±36.3 103±34.7 94.6±37.1 ns
Indexed LVEDV, mL/m2 56.5±19.1 60.4±18.7 54.2±19.1 ns
LVEF, % 56±12.6 55.5±11.5 56.3±13.2 ns
LV mass, g 250.0±80.4 261.5±91.1 243.1±73.0 ns
Indexed LV mass, g/m2 145.5±45.9 154.8±54.1 139.8±39.4 0.0964
Significant LVH, % 68.1 69.8 67.1 ns
LAV, mL 71.7±27.4 69.6±30.5 72.9±25.5 ns
Indexed LAV, mL/m2 41.8±16.8 41.1±20.0 42.2±14.8 ns
BSA, body surface area; CAD, coronary artery disease; NYHA, New York Heart Association; AVA, aortic 
valve area; LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle ejection fraction; LVH, left ventricle 
hypertrophy; LAV, left atrial volume. The figures in the fields show means ± standard deviation for continuous 
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patients (68.1%) having significant (moderate or severe) 
LV hypertrophy (considering ≥132 g/m2 for men and 
≥109 g/m2 in women as the cut-off for moderate hyper-
trophy).
Evolution of AS Severity, Chamber Volumes, LV 
Mass and Function and Myocardial Deformation 
Parameters
The first echocardiographic examination (V1) was 
performed a median of 1 (1–2) days prior to the interven-
tion, the second (V2) a median of 5 (4–7) days after 
the  procedure, the intermediate (V3) a median of 188 
(183–195) days after the intervention and the last exami-
nation (FV) 370 (366–377) days after the procedure.
The echocardiographic parameters measured at each 
visit are listed in Table 2. Predictably, parameters of AS 
severity suffered a profound change 1 year after the TAVR 
procedure, with a significant decrease in transvalvular 
gradients (mean aortic gradient from 46.3 ± 15.0 to 
11.7 ±10.6 mm Hg, p < 0.001; peak aortic gradient from 
76.3 ± 26.2 to 21.7 ± 17.3 mm Hg, p < 0.001) and a sig-
nificant increase in aortic valve area (from 0.75 ± 0.23 to 
1.68  ± 0.56 cm2, p < 0.001). A significant reduction in 
LV indexed mass was also noted (from 145.5 ± 45.9 to 
120.1 ± 37.2 g/m2, p = 0.0002). Nevertheless, systolic 
function as assessed by LVEF measured by the Simpson 
biplane method remained unaltered (from 56 ± 12.5 to 
57.8 ± 11.8%, p = 0.3911). In contrast with this, GLS 
showed a progressive and statistically significant reduc-
tion throughout the examinations (–14.6 ± 5.0% at V1; 
–15.7 ± 5.1% at V2, p = 0.0116; –18.1 ± 4.7% at V3, p = 
0.0004; –17.1 ± 4.9% at FV, p < 0.001). This improvement 
was seen both in the group of patients with low ejection 
fraction at baseline (defined as < 50% by the Simpson bi-
plane method), which showed GLS of –10.9 ± 4.1% at V1, 
–12.1 ± 4.3% at V2, p = 0.0265, –14.6 ± 5.6 at V3, p = 0.19, 
and –14.2 ± 5.5 at FV, p = 0.141, and in the group of pa-
tients with normal ejection fraction, which showed GLS of 
–16.5 ± 4.5 at V1, –17.2 ± 4.8 at V2, p = 0.1506, –19.3 ± 4.1 
at V3, p = 0.120, and –18.3 ± 4.2 at FV, p = 0.0002.
The results of the 1-way repeated-measures ANOVA 
showed that GLS was statistically different over the course 
of the study, F(3, 233) = 11.01 (p < 0.0001).
Evolution of AS Severity, Chamber Volumes and LV 
Mass and Function according to Type of Valve
Differences in baseline parameters were presented in 
Table 1. Differences in echocardiographic parameters at 
each examination according to valve subtype are shown 
in Table 3.
Notably, a slightly superior decrease in transaortic gra-
dients and increase in effective orifice area were seen in 
the CoreValve group, while LV end-diastolic volume, 
LVEF, indexed mass and left atrial volume were compa-
rable between groups at each examination.
Evolution of LV Mechanics Improvement according to 
Type of Valve
In a longitudinal subgroup analysis, a differential 
behaviour in GLS evolution could be appreciated ac-
Table 2. Evolution of echocardiographic parameters at each visit






Mean gradient, mm Hg 46.3±15.0 12±7.9 <0.001 11.7±7.8 <0.001 11.7±10.6 <0.001
Peak gradient, mm Hg 76.3±26.2 21.6±12.8 <0.001 21.6±13.3 <0.001 21.7±17.3 <0.001
AVA/EOA, m2 0.75±0.23 1.94±0.59 <0.001 1.86±0.67 <0.001 1.68±0.56 <0.001
Indexed AVA/EOA, cm2/m2 0.44±0.17 1.12±0.36 <0.001 1.07±0.41 <0.001 1.02±0.34 <0.001
LVEDV, mL 97.8±36.3 92.7±33.4 0.0017 86.6±28.7 0.0697 97.6±30.6 ns
Indexed LVEDV, mL/m2 56.5±19.1 53.8±17.9 0.0024 50.6±15.8 0.0882 56.7±16.5 ns
LVEF, % 56±12.5 56.8±11.5 ns 61.4±10.0 0.0260 57.8±11.8 ns
Indexed mass, g/m2 145.5±45.9 132.3±41.3 0.0009 123.2±33.5 0.0001 120.1±37.2 0.0002
LAV, mL 71.7±27.4 64.8±25.2 0.0339 67.8±29.9 0.0965 64.4±26.7 0.0528
Indexed LAV, mL/m2 41.8±16.8 37.7±16.4 0.0853 39.7±17.6 0.0838 39.3±16.2 ns
GLS, % –14.6±5.0 –15.7±5.1 0.0116 –18.1±4.7 0.0004 –17.1±4.9 <0.001
V1, visit 1; V2, visit 2; V3, visit 3; FV, final visit; AVA, aortic valve area; EOA, effective orifice area; LVEDV, left ventricle end-diastolic 
volume; LVEF, left ventricle ejection fraction; LAV, left atrial volume; GLS, global longitudinal strain. The figures in the fields show 











































































cording to valve subtype (Table 4). In the CoreValve 
group, an immediate significant improvement in GLS 
could be noted at V2, with a further significant de-
crease in consecutive examinations (–14.3 ± 5.0% at 
V1; –17.1 ± 5.7% at V2, p < 0.0001; –20.3 ± 4.6% at V3, 
p = 0.0010; –17.6 ± 5.1% at FV, p < 0.0001). The 1-way 
repeated-measures ANOVA showed a statistically sig-
nificant improvement in GLS along the different time 
points, F(3, 95) = 11.86 (p < 0.0001). In the Lotus group, 
a gradual reduction in GLS could be seen throughout 
the examinations, only achieving a significant reduc-
tion 1 year after valve replacement (–14.8 ± 5.0% at 
V1; –14.9 ± 4.9% at V2, p = 0.9155; –16.7 ± 4.4 at V3, 
p = 0.0775; –17.1 ± 4.9% at FV, p < 0.0001). The 1-way 
repeated-measures ANOVA showed a statistically sig-
nificant improvement in GLS along the different time 
points, F(3, 135) = 2.89 (p = 0.0380). If compared trans-
versally, a statistically significant difference in GLS be-
tween valve subtypes could be seen at V2 and V3, but 
not at FV (Table 3).
Figure 2 presents box plots of GLS at each visit for each 
valve subtype. The effective orifice area after TAVR was 
calculated using postimplantation LV outflow tract diam-
eter, LV outflow tract velocity-time integrals with the 
pulsed-wave Doppler sample volume at the proximal 
edge of the valve stent and velocity-time integrals across 
the prosthesis measured by continuous-wave Doppler so-
nography.
Table 3. Differences in echocardiographic parameters at each examination according to valve subtype
V2 V3 FV
CoreValve lotus p value CoreValve lotus p value CoreValve lotus p value
Mean gradient,
mm Hg 9.8±9.6 13.5±6.2 0.0166 8.8±3.6 14±9.4 0.0264 7.7±2.7 16.5±14.4 0.0004
Peak gradient,
mm Hg 18.3±15.1 23.7±10.6 0.0348 16.8±5.9 25.5±16.0 0.0292 15.9±11.7 28.7±20.7
0.0020
EOA, m2 2.10±0.65 1.83±0.53 0.0306 2.10±0.60 1.61±0.66 0.0058 2.0±0.54 1.35±0.4 <0.0001
Indexed EOA, 
cm2/m2 1.23±0.39 1.05±0.32 0.0210 1.31±0.37 0.90±0.35 0.0007 1.21±0.32 0.80±0.21 <0.0001
LVEDV, mL 98.3±37.7 88.6±30.3 ns 73.2±23.1 94.8±29.7 0.0281 101.9±35.0 91.6±23.8 ns
Indexed LVEDV,
mL/m2 57.5±20.0 51.1±15.9 0.0900 44.7±13.7 54.4±16.5 0.0761 54.9±18.5 53.4±13.2 ns
LVEF, % 58.2±11.0 55.9±11.9 ns 65±7.3 59.7±11.1 0.0898 57.5±12.9 58.5±10.4 ns
Indexed mass,
g/m2 138±40.1 128.5±41.9 ns 117.4±44.1 124.8±25.4 ns 118.6±32.6 122±43.0 ns
LAV, mL 64±30.9 65.3±20.9 ns 68.5±27.0 67.5±32.4 ns 62.9±31.3 66.5±20.1 ns
Indexed LAV,
mL/m2 37.8±19.1 37.7±14.5 ns 41±18.0 39.2±17.9 ns 40.4±20.0 38.3±11.0 ns
GLS, % –17.1±5.7 –14.9±4.5 0.0320 –20.8±4.1 –16.8±4.4 0.0025 –17.6±5.1 –16.6±4.7 ns
V2, visit 2; V3, visit 3; FV, final visit; EOA, effective orifice area; LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle 
ejection fraction; LAV, left atrial volume; GLS, global longitudinal strain. The figures in the fields show means ± standard deviation for 
continuous variables and percentages for qualitative variables.
Table 4. Evolution of global longitudinal strain (%) according to valve subtype






CoreValve –14.3±5.0 –17.1±5.7 <0.0001 –20.3±4.6 0.0010 –17.6±5.1 <0.0001
Lotus –14.8±5.0 –14.9±4.9 ns –16.7±4.4 0.0775 –16.5±4.6 0.0176
Global –14.6±5.0 –15.7±5.1 <0.0116 –18.1±4.7 0.0004 –17.1±4.9 <0.0001
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Prediction of GLS Improvement according to Baseline 
Characteristics
A multiple regression was run to predict the difference 
in GLS at FV, including various anthropometric and 
echocardiographic parameters obtained at V1. After a 
stepwise regression, GLS at baseline, type of valve used, 
mean aortic gradient and presence of significant mitral 
calcification were found to best predict GLS at FV. These 
variables statistically significantly predicted the differ-
ence in GLS (%) at FV, F(4, 83) = 11.58, p < 0.0001, R2 = 
0.3583. All four variables added statistically significantly 
to the prediction, p < 0.05. The variables included in the 
final model and their statistical significance are shown at 
Table 5. A graphic representation of the relationship be-
tween GLS and the continuous variables included in the 
model (GLS at baseline and valve subtype) can be seen in 
Figures 3 and 4.
Discussion
The main findings of this study are as follows: (i) 
TAVR is associated with an immediate and sustained im-
provement in LV mechanics, as demonstrated by GLS re-
duction, (ii) this occurs although LV systolic function, as 
assessed by LVEF by Simpson’s biplane method, remains 
unaltered, (iii) the profile of GLS improvement differs be-
tween valve subtype, with only the CoreValve group 
showing a statistically significant reduction in GLS im-
mediately after device implantation and both the CoreV-
alve and the Lotus group ensuring a statistically signifi-
cant reduction in GLS 1 year after valve replacement.
Patient Population
We think the population included in the study accu-
rately represents that of severe AS patients usually re-
ferred for a TAVR procedure, with similar characteristics 
to the population included in the intermediate-risk pa-
tient study [30, 31].
Effect of TAVR in LV Geometry
Severe AS causes a chronic pressure overload that 
leads to a pathological remodelling in the form of concen-
tric hypertrophy, with an increase in LV mass and myo-
cardial fibrosis. TAVR causes an acute and sustained de-
crease in transvalvular gradient that could favour reverse 
remodelling. An immediate reduction in indexed LV 
mass was also seen, a finding also seen in previous studies, 
both with TAVR and surgical replacement [32–34]. Giv-
en that this change could hardly be explained by changes 
in myocyte size or number, protein synthesis, organiza-
tion of the sarcomere or fibrosis, we propose that this 
change could represent a reduction in myocardial oede-
ma, as seen in myocarditis [35]. In our opinion, this could 
represent the first landmark of an incipient reverse re-
modelling.
Effect of TAVR in LV Performance
In this study, with a follow-up of 1 year and 2 interme-
diate echocardiographic examinations, no change was 
noted in systolic function, which was largely normal pri-
or to the procedure, but an otherwise significant reduc-
tion in GLS was seen.
In a stratified analysis according to valve subtype, 
the Lotus group showed a delayed improvement in GLS 
compared to the CoreValve group, reaching a statisti-
cally significant longitudinal difference only at FV, but 
without significant differences between the two groups 
at the end of the study. This finding could be ex-




GLS (%) at baseline –0.355 (0.0866) <0.01
Mean aortic gradient 0.0803 (0.0278) <0.01
Type of valve (Lotus) –2.019 (0.815) <0.05
Mitral calcification (yes) 1.845 (0.893) <0.05










































Fig. 2. Evolution of global longitudinal strain by valve subtype. The 
figure shows boxplots for global longitudinal strain (%) for each 
valve subtype at each study visit. * p < 0.05: statistically significant-




























































































plained by the lightly superior reduction in transaortic 
gradients and increment in effective orifice area ob-
tained by the CoreValve, which may facilitate an im-
provement in LV performance earlier at follow-up. 
This, in turn, could be explained by the different archi-
tecture of both prostheses, which confers a supravalvu-
lar position of the prosthetic leaflets in the case of the 
CoreValve which may help maximize the effective ori-
fice area.
Limitations of the Study
The main limitations of this analysis are the relatively 
small sample size and the lack of randomization between 
the groups.
Radial and circumferential strain values were not col-
lected in the study, mainly because GLS is more wide-
spread and reproducible, so we considered it to be the 
more relevant parameter of LV mechanics for clinical ap-
plication. Thus, potential changes in radial and circum-
ferential deformation could not be studied.
We decided to consider all GLS data available, regard-
less of the echocardiographic machine employed at each 
centre, provided that the same machine was used for ev-
ery study in the same patient, and so, 5 different scanners 
from 3 different manufacturers were used. Although in-
ter-vendor variability makes it difficult to directly com-
pare a given GLS value between two different machines 
because of the different algorithms used by the manufac-
turers, studies comparing strain measurements among 
different vendors have found only small variations from 
one to another [36]. With that in mind, we expected that 
the procedure would elicit an improvement in GLS of the 
same magnitude for every vendor used that would over-
come this obstacle. However, we do not know whether 
our findings could represent an underestimation of the 
effect of TAVR over GLS if a single vendor was employed.
Conclusions
Although LVEF remained unaltered after TAVR, an 
immediate and sustained improvement in GLS could be 
appreciated. This evolution of changes in LV mechanics 
was different between valve subtypes, with an earlier re-
duction of GLS in the CoreValve group, although the Lo-
tus group proved a similar benefit 1 year after TAVR. 
Whether this finding continues to be noted in a more pro-
longed follow-up and its clinical implications need to be 
assessed in further studies.
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Fig. 3. Graphic representation of the relationship between the dif-
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Fig. 4. Graphic representation of the relationship between the dif-
ference in global longitudinal strain (GLS; %) at final visit and 
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